AI Article Synopsis
- Alternative splicing (AS) is a key process that allows a single gene to produce multiple protein variants, playing crucial roles in development and tissue maintenance, while errors in AS are linked to various diseases, especially cancer.
- Cancer-specific AS isoforms can serve as biomarkers for diagnosis and prognosis, as well as potential targets for anti-cancer treatments.
- The text emphasizes the role of AS regulation in cancer angiogenesis, highlighting specific AS variants and regulators that affect angiogenic factors, which could be promising targets for new cancer therapies.
Article Abstract
Alternative splicing (AS) is a pervasive molecular process generating multiple protein isoforms, from a single gene. It plays fundamental roles during development, differentiation and maintenance of tissue homeostasis, while aberrant AS is considered a hallmark of multiple diseases, including cancer. Cancer-restricted AS isoforms represent either predictive biomarkers for diagnosis/prognosis or targets for anti-cancer therapies. Here, we discuss the contribution of AS regulation in cancer angiogenesis, a complex process supporting disease development and progression. We consider AS programs acting in a specific and non-redundant manner to influence morphological and functional changes involved in cancer angiogenesis. In particular, we describe relevant AS variants or splicing regulators controlling either secreted or membrane-bound angiogenic factors, which may represent attractive targets for therapeutic interventions in human cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720527 | PMC |
| http://dx.doi.org/10.1186/s13046-020-01753-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!